Qiagen NVHorizion EuropePharmahungary Group participates in ambiti...Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next … more ➔
Alentis TherapeuticsFinancingAlentis Therapeutics raises US$181.4m in S...Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours. more ➔
BIOCOMPEGS Europe 2024Next-gen antibody formats presented at PEG...Biotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several … more ➔
Memorial Sloan Kettering Cancer CentreEarly cancer detectionHarbinger Health to speed up clinical canc...US spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study … more ➔
Novo NordiskCollaborationNovo Nordisk signs deal for monthly GLP-1...Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing … more ➔
ProBioGenCancer vaccinesTransgene and ProBioGen forge partnershipThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccine … more ➔
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038Novo NordiskNovo’s obesity blockbuster semagluti...In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity bloc … more ➔
© Niclas Jessen Studio/Bracco Imaging SpAFinancingBlue Therapeutics gets financing to push r...Radiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) … more ➔
EniferNovel FoodEnifer files for EFSA authorisation of myc...As the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA. more ➔
Knowledge Seeker - wikipedia.orgDigital PathologyAIgnostics raises US$34m in Series B finan...Digital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and … more ➔